MAP2K7 and cancer: Binimetinib, cobimetinib, and selumetinib, all MEK inhibitors, clustered together and shared many targets, such as ETV1, ETV4 and ETV5, which play crucial roles in development, organogenesis, and cell proliferation, and are also implicated in cancer; or MAP3K1 and TNFRSF14 which are involved in the regulation of cell migration, survival, and apoptosis.